ISIAKA BOLARINWA: Open Payments
NPI 1467403196 · GLOUCESTER CITY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,195 in 74 payments from 12 companies in 2025. Trend: 2023 $821 · 2024 $1,158 · 2025 $1,195
Food & beverage: $1,195
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $197 |
| ABBVIE INC. | 15 | $193 |
| Alkermes, Inc. | 12 | $193 |
| Teva Pharmaceuticals USA, Inc. | 12 | $140 |
| E.R. Squibb & Sons, L.L.C. | 6 | $105 |
| Janssen Pharmaceuticals, Inc | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Lundbeck LLC | 2 | $38 |
Products named: INGREZZA, VRAYLAR, REXULTI, ARISTADA, COBENFY, LYBALVI, AUSTEDO XR, UZEDY.
Industry payments across NJ — which companies pay providers there.
